GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Poniard Pharmaceuticals Inc (OTCPK:PARD) » Definitions » Operating Margin %
中文

Poniard Pharmaceuticals (Poniard Pharmaceuticals) Operating Margin %

: 0.00% (As of Sep. 2011)
View and export this data going back to 2012. Start your Free Trial

Operating Margin % is calculated as Operating Income divided by its Revenue. Poniard Pharmaceuticals's Operating Income for the three months ended in Sep. 2011 was $-3.75 Mil. Poniard Pharmaceuticals's Revenue for the three months ended in Sep. 2011 was $0.00 Mil. Therefore, Poniard Pharmaceuticals's Operating Margin % for the quarter that ended in Sep. 2011 was 0.00%.

The historical rank and industry rank for Poniard Pharmaceuticals's Operating Margin % or its related term are showing as below:


PARD's Operating Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -177.8
* Ranked among companies with meaningful Operating Margin % only.

Poniard Pharmaceuticals's 5-Year Average Operating Margin % Growth Rate was 0.00% per year.

Poniard Pharmaceuticals's Operating Income for the three months ended in Sep. 2011 was $-3.75 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Sep. 2011 was $-15.53 Mil.


Poniard Pharmaceuticals Operating Margin % Historical Data

The historical data trend for Poniard Pharmaceuticals's Operating Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Poniard Pharmaceuticals Annual Data
Trend Dec01 Dec02 Dec03 Dec04 Dec05 Dec06 Dec07 Dec08 Dec09 Dec10
Operating Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Poniard Pharmaceuticals Quarterly Data
Dec06 Mar07 Jun07 Sep07 Dec07 Mar08 Jun08 Sep08 Dec08 Mar09 Jun09 Sep09 Dec09 Mar10 Jun10 Sep10 Dec10 Mar11 Jun11 Sep11
Operating Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison

For the Biotechnology subindustry, Poniard Pharmaceuticals's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Poniard Pharmaceuticals Operating Margin % Distribution

For the Biotechnology industry and Healthcare sector, Poniard Pharmaceuticals's Operating Margin % distribution charts can be found below:

* The bar in red indicates where Poniard Pharmaceuticals's Operating Margin % falls into.



Poniard Pharmaceuticals Operating Margin % Calculation

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

Poniard Pharmaceuticals's Operating Margin % for the fiscal year that ended in Dec. 2010 is calculated as

Operating Margin %=Operating Income (A: Dec. 2010 ) / Revenue (A: Dec. 2010 )
=-26.332 / 0
= %

Poniard Pharmaceuticals's Operating Margin % for the quarter that ended in Sep. 2011 is calculated as

Operating Margin %=Operating Income (Q: Sep. 2011 ) / Revenue (Q: Sep. 2011 )
=-3.748 / 0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Poniard Pharmaceuticals  (OTCPK:PARD) Operating Margin % Explanation

Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.


Be Aware

Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia’s Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


Poniard Pharmaceuticals Operating Margin % Related Terms

Thank you for viewing the detailed overview of Poniard Pharmaceuticals's Operating Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Poniard Pharmaceuticals (Poniard Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
300 Elliott Avenue West, Suite 530, Seattle, CA, USA, 98119
Poniard Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of cancer therapeutics. Its product candidate is picoplatin, a new generation platinum-based cancer therapy.
Executives
Michael S Perry officer: President & CMO C/O BIOTRANSPLANT INC, 196 BOSTON AVE SUITE 2800, MEDFORD MA 02155
Ron Martell director, officer: Chief Executive Officer PONIARD PHARMACEUTICALS, INC., 750 BATTERY STREET, SUITE 330, SAN FRANCISCO CA 94111
Gary A Lyons director 12790 EL CAMINO REAL, C/O NEUROCRINE BIOSCIENCES, SAN DIEGO CA 92130
David R Stevens director 300 ELLIOTT AVENUE WEST, SUITE 500, SEATTLE WA 98119-4114
Gerald Phd Mcmahon director 300 ELLIOTT AVENUE WEST, SUITE 500, SEATTLE WA 98119-4114
Carl Goldfischer director 161 WEST 61ST STREET, NEW YORK NY 10022
Fred B Craves director 750 BATTERY ST, STE 600, SAN FRANCISCO CA 94111
Simon Nicholas J Iii director, 10 percent owner THE JOHN HANCOCK TOWER, 200 CLARENDON STREET, 54TH FLOOR, BOSTON MA 02116
Gregory L Weaver officer: Chief Financial Officer 185 BERRY STREET, SUITE 6504, SAN FRANCISCO CA 94107
Kurt Wheeler 10 percent owner 801 GATEWAY BLVD, STE 410, SAN FRANCISCO CA 94080
Mpm Asset Management Investors 2005 Bviii Llc 10 percent owner C/O MPM ASSET MANAGEMENT, 111 HUNTINGTON AVENUE 31ST FLOOR, BOSTON MA 02199
Nicholas Galakatos 10 percent owner THE JOHN HANCOCK TOWER, 200 CLARENDON STREET, 54TH FLOOR, BOSTON MA 02116
Dennis Henner 10 percent owner THE JOHN HANCOCK TOWER, 200 CLARENDON STREET, 54TH FLOOR, BOSTON MA 02116
Michael Steinmetz 10 percent owner THE JOHN HANCOCK TOWER, 200 CLARENDON STREET, 54TH FLOOR, BOSTON MA 02116
Luke Evnin 10 percent owner THE JOHN HANCOCK TOWER, 200 CLARENDON STREET, 54TH STREET, BOSTON MA 02116

Poniard Pharmaceuticals (Poniard Pharmaceuticals) Headlines